Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.PubMed/NCBI View Article : Google Scholar

Ng KL: The Etiology of Prostate Cancer. In: Prostate Cancer. Bott SRJ and Ng KL (eds). Exon Publications, Brisbane, Queensland, 2021.

Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A and Mashele S: Prostate cancer review: Genetics, diagnosis, treatment options, and alternative approaches. Molecules. 27(5730)2022.PubMed/NCBI View Article : Google Scholar

Adamaki M and Zoumpourlis V: Prostate cancer biomarkers: From diagnosis to prognosis and precision-guided therapeutics. Pharmacol Ther. 228(107932)2021.PubMed/NCBI View Article : Google Scholar

Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, et al: Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 71:6503–6513. 2011.PubMed/NCBI View Article : Google Scholar

Hellmis E, Schwentner C, Mandel P, Banek S, Gleissner J and Bogemann M: Apalutamide in patients with high-risk M0CRPC: Data from the pivotal SPARTAN study and initial experience from a compassionate use program. Aktuelle Urol. 54:140–147. 2023.PubMed/NCBI View Article : Google Scholar : (In German).

Rajaram P, Rivera A, Muthima K, Olveda N, Muchalski H and Chen QH: Second-generation androgen receptor antagonists as hormonal therapeutics for three forms of prostate cancer. Molecules. 25(2448)2020.PubMed/NCBI View Article : Google Scholar

Shen J, Chowdhury S, Agarwal N, Karsh LI, Oudard S, Gartrell BA, Feyerabend S, Saad F, Pieczonka CM, Chi KN, et al: Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN. Br J Cancer. 130:73–81. 2024.PubMed/NCBI View Article : Google Scholar

Ruiz de Porras V, Font A and Aytes A: Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives. Cancer Lett. 523:162–169. 2021.PubMed/NCBI View Article : Google Scholar

Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, Johnson A, Jendrisak A, Bambury R, Danila D, et al: Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 2:1441–1449. 2016.PubMed/NCBI View Article : Google Scholar

Deluce JE, Cardenas L, Lalani AK, Maleki Vareki S and Fernandes R: Emerging Biomarker-guided therapies in prostate cancer. Curr Oncol. 29:5054–5076. 2022.PubMed/NCBI View Article : Google Scholar

Asif S and Teply BA: Biomarkers for treatment response in advanced prostate cancer. Cancers (Basel). 13(5723)2021.PubMed/NCBI View Article : Google Scholar

Singh P, Patel M, Bhowmik D, Kumari N, Prajapati KS and Gupta R: Identification of common biomarkers affecting patient survival in cancers. World Acad Sci. 6:1–12. 2024.

Patel M, Singh P, Gandupalli L and Reeshu G: Identification and evaluation of Survival-associated common chemoresistant genes in cancer. Biomed Biotechnol Res J. 8:320–327. 2024.

Chen JY, Wang PY, Liu MZ, Lyu F, Ma MW, Ren XY and Gao XS: Biomarkers for prostate cancer: From diagnosis to treatment. Diagnostics (Basel). 13(3350)2023.PubMed/NCBI View Article : Google Scholar

Pires FR, Sagarra R, Corrêa ME, Pereira CM, Vargas PA and Lopes MA: Oral metastasis of a hepatocellular carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 97:359–368. 2004.PubMed/NCBI View Article : Google Scholar

Sobhani N, Neeli PK, D'Angelo A, Pittacolo M, Sirico M, Galli IC, Roviello G and Nesi G: AR-V7 in metastatic prostate cancer: A strategy beyond redemption. Int J Mol Sci. 22(5515)2021.PubMed/NCBI View Article : Google Scholar

Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, et al: Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69:16–22. 2009.PubMed/NCBI View Article : Google Scholar

Katleba KD, Ghosh PM and Mudryj M: Beyond prostate cancer: An androgen receptor splice variant expression in multiple malignancies, non-cancer pathologies, and development. Biomedicines. 11(2215)2023.PubMed/NCBI View Article : Google Scholar

Ferguson DC, Mata DA, Tay TK, Traina TA, Gucalp A, Chandarlapaty S, D'Alfonso TM, Brogi E, Mullaney K, Ladanyi M, et al: Androgen receptor splice variant-7 in breast cancer: Clinical and pathologic correlations. Mod Pathol. 35:396–402. 2022.PubMed/NCBI View Article : Google Scholar

Lieberman AP and Robins DM: The androgen receptor's CAG/glutamine tract in mouse models of neurological disease and cancer. J Alzheimers Dis. 14:247–255. 2008.PubMed/NCBI View Article : Google Scholar

Dauki AM, Blachly JS, Kautto EA, Ezzat S, Abdel-Rahman MH and Coss CC: Transcriptionally active androgen receptor splice variants promote hepatocellular carcinoma progression. Cancer Res. 80:561–575. 2020.PubMed/NCBI View Article : Google Scholar

Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, Russo JW, Figueiredo I, Bertan C, Seed G, et al: Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J Clin Invest. 129:192–208. 2019.PubMed/NCBI View Article : Google Scholar

Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K and Sawyers CL: Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA. 107:16759–16765. 2010.PubMed/NCBI View Article : Google Scholar

Wang Z, Shen H, Liang Z, Mao Y, Wang C and Xie L: The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: A systematic review and meta-analysis. Cancer Cell Int. 20(149)2020.PubMed/NCBI View Article : Google Scholar

König P, Eckstein M, Jung R, Abdulrahman A, Guzman J, Weigelt K, Serrero G, Hayashi J, Geppert C, Stöhr R, et al: Expression of AR-V7 (androgen receptor variant 7) protein in granular cytoplasmic structures is an independent prognostic factor in prostate cancer patients. Cancers (Basel). 12(2639)2020.PubMed/NCBI View Article : Google Scholar

Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, et al: Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 72:3457–3462. 2012.PubMed/NCBI View Article : Google Scholar

Bevan CL, Hoare S, Claessens F, Heery DM and Parker MG: The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol. 19:8383–8392. 1999.PubMed/NCBI View Article : Google Scholar

Chen Z, Wu D, Thomas-Ahner JM, Lu C, Zhao P, Zhang Q, Geraghty C, Yan PS, Hankey W, Sunkel B, et al: Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. Proc Natl Acad Sci USA. 115:6810–6815. 2018.PubMed/NCBI View Article : Google Scholar

Dai C, Dehm SM and Sharifi N: Targeting the androgen signaling axis in prostate cancer. J Clin Oncol. 41:4267–4278. 2023.PubMed/NCBI View Article : Google Scholar

Mostaghel EA: Alternative acts: Oncogenic splicing of steroidogenic enzymes in prostate cancer. Clin Cancer Res. 25:1139–1141. 2019.PubMed/NCBI View Article : Google Scholar

Henzler C, Li Y, Yang R, McBride T, Ho Y, Sprenger C, Liu G, Coleman I, Lakely B, Li R, et al: Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Nat Commun. 7(13668)2016.PubMed/NCBI View Article : Google Scholar

Zhang T, Karsh LI, Nissenblatt MJ and Canfield SE: Androgen receptor splice variant, AR-V7, as a biomarker of resistance to androgen Axis-targeted therapies in advanced prostate cancer. Clin Genitourin Cancer. 18:1–10. 2020.PubMed/NCBI View Article : Google Scholar

Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, et al: Niclosamide and bicalutamide combination treatment overcomes Enzalutamide- and bicalutamide-resistant prostate cancer. Mol Cancer Ther. 16:1521–1530. 2017.PubMed/NCBI View Article : Google Scholar

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, et al: Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 1:582–591. 2015.PubMed/NCBI View Article : Google Scholar

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, ilberstein JL, Taylor MN, Maughan BL, Denmeade SR, et al: Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with First- and Second-line abiraterone and enzalutamide. J Clin Oncol. 35:2149–2156. 2017.PubMed/NCBI View Article : Google Scholar

Kono M, Fujii T, Lim B, Karuturi MS, Tripathy D and Ueno NT: Androgen receptor function and androgen Receptor-targeted therapies in breast cancer: A review. JAMA Oncol. 3:1266–1273. 2017.PubMed/NCBI View Article : Google Scholar

Gatalica Z, Hoag J, Hall DW, Alyaqoub FS, Dombrowski S, Noel P, Szelinger S, Udhane S, Min W and Thakkar SG: CGE23-072: The frequency of androgen receptor splice Variant 7 (AR-V7) in solid tumors. J Nat Comprehensive Nat Netw. 21:2023.

Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell CJ, et al: Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in High-risk Castration-resistant prostate cancer: The PROPHECY Study. J Clin Oncol. 37:1120–1129. 2019.PubMed/NCBI View Article : Google Scholar

Carles J, Alonso-Gordoa T, Mellado B, Mendez-Vidal MJ, Vazquez S, Gonzalez-Del-Alba A, Piulats JM, Borrega P, Gallardo E, Morales-Barrera R, et al: Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial. Eur J Cancer. 173:317–3126. 2022.PubMed/NCBI View Article : Google Scholar

Shenderov E, Boudadi K, Fu W, Wang H, Sullivan R, Jordan A, Dowling D, Harb R, Schonhoft J, Jendrisak A, et al: Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial. Prostate. 81:326–338. 2021.PubMed/NCBI View Article : Google Scholar

Tewari A: AMG 160 aH-LE, PSMA-Targeted, Bispecific T-cell Engager (BiTE^®) immune Therapy for mCRPC-Interim Results From a Phase I Study. [(Accessed on 30 April 2021)]; Available online: https://www.urotoday.com/conference-highlights/esmo-2020/prostate-cancer/124632-esmo-virtual-congress-2020-amg-160-a-half-life-extended-psma-targeted-bispecific-t-cell-engager-bite-immune-therapy-for-mcrpc-interim-results-from-a-phase-i-study.html.

Li W, Zhang B, Tang J, Cao Q, Wu Y, Wu C, Guo J, Ling EA and Liang F: Sirtuin 2, a mammalian homolog of yeast silent information regulator-2 longevity regulator, is an oligodendroglial protein that decelerates cell differentiation through deacetylating alpha-tubulin. J Neurosci. 27:2606–2616. 2007.PubMed/NCBI View Article : Google Scholar

Rana Z, Diermeier S, Hanif M and Rosengren RJ: Understanding failure and improving treatment using HDAC inhibitors for prostate cancer. Biomedicines. 8(22)2020.PubMed/NCBI View Article : Google Scholar

Eckschlager T, Plch J, Stiborova M and Hrabeta J: Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 18(1414)2017.PubMed/NCBI View Article : Google Scholar

Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, von Deimling A, et al: Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res. 15:91–99. 2009.PubMed/NCBI View Article : Google Scholar

Wang L, Zou X, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, et al: Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res. 1:62–71. 2009.PubMed/NCBI

Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, et al: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 98:604–610. 2008.PubMed/NCBI View Article : Google Scholar

Shankar E, Pandey M, Verma S, Abbas A, Candamo M, Kanwal R, Shukla S, MacLennan GT and Gupta S: Role of class I histone deacetylases in the regulation of maspin expression in prostate cancer. Mol Carcinog. 59:955–966. 2020.PubMed/NCBI View Article : Google Scholar

Waltregny D, North B, Van Mellaert F, de Leval J, Verdin E and Castronovo V: Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. Eur J Histochem. 48:273–290. 2004.PubMed/NCBI

Li Y and Seto E: HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 6(a026831)2016.PubMed/NCBI View Article : Google Scholar

Zeng LS, Yang XZ, Wen YF, Mail SJ, Wang MH, Zhang MY, Zheng XF and Wang HY: Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma. Aging (Albany NY). 8:1236–1249. 2016.PubMed/NCBI View Article : Google Scholar

Beaver LM, Lӧhr CV, Clarke JD, Glasser ST, Watson GW, Wong CP, Zhang Z, Williams DE, Dashwood RH, Shannon J, et al: Broccoli sprouts delay prostate cancer formation and decrease prostate cancer severity with a concurrent decrease in HDAC3 protein expression in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice. Curr Dev Nutr. 2(nzy002)2018.PubMed/NCBI View Article : Google Scholar

Jang YG, Hwang KA and Choi KC: Rosmarinic acid, a component of rosemary tea, induced the cell cycle arrest and apoptosis through modulation of HDAC2 expression in prostate cancer cell lines. Nutrients. 10(1784)2018.PubMed/NCBI View Article : Google Scholar

Pandey M, Kaur P, Shukla S, Abbas A, Fu P and Gupta S: Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: In vitro and in vivo study. Mol Carcinog. 51:952–962. 2012.PubMed/NCBI View Article : Google Scholar

Zhang L, Zhang J, Jiang Q, Zhang L and Song W: Zinc binding groups for histone deacetylase inhibitors. J Enzyme Inhib Med Chem. 33:714–721. 2018.PubMed/NCBI View Article : Google Scholar

Yue K, Qin M, Huang C, James Chou C, Jiang Y and Li X: Comparison of three zinc binding groups for HDAC inhibitors-A potency, selectivity and enzymatic kinetics study. Bioorg Med Chem Lett. 70(128797)2022.PubMed/NCBI View Article : Google Scholar

Moi D, Bonanni D, Belluti S, Linciano P, Citarella A, Franchini S, Sorbi C, Imbriano C, Pinzi L and Rastelli G: Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancer. Eur J Med Chem. 260(115730)2023.PubMed/NCBI View Article : Google Scholar

Eigl BJ, North S, Winquist E, Finch D, Wood L, Sridhar SS, Powers J, Good J, Sharma M, Squire JA, et al: A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. Invest New Drugs. 33:969–976. 2015.PubMed/NCBI View Article : Google Scholar

Ferrari AC, Alumkal JJ, Stein MN, Taplin ME, Babb J, Barnett ES, Gomez-Pinillos A, Liu X, Moore D, DiPaola R and Beer TM: Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer. Clin Cancer Res. 25:52–63. 2019.PubMed/NCBI View Article : Google Scholar

Biersack B, Nitzsche B and Hopfner M: HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer. Cancer Drug Resist. 5:64–79. 2022.PubMed/NCBI View Article : Google Scholar

Chen Z, Wang X, Yang X, Xu Y, Yang Y, Wang H, Li T, Bai P, Yuan G, Chen H, et al: Imaging assisted evaluation of antitumor efficacy of a new histone deacetylase inhibitor in the castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 48:53–66. 2021.PubMed/NCBI View Article : Google Scholar

Rosati R, Chen B, Patki M, McFall T, Ou S, Heath E, Ratnam M and Qin Z: Hybrid Enzalutamide derivatives with histone deacetylase inhibitor activity decrease heat shock protein 90 and androgen receptor levels and inhibit viability in Enzalutamide-resistant C4-2 prostate cancer cells. Mol Pharmacol. 90:225–237. 2016.PubMed/NCBI View Article : Google Scholar

Hu WY, Xu L, Chen B, Ou S, Muzzarelli KM, Hu DP, Li Y, Yang Z, Vander Griend DJ, Prins GS and Qin Z: Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75. Prostate. 79:1166–1179. 2019.PubMed/NCBI View Article : Google Scholar

Sun H, Mediwala SN, Szafran AT, Mancini MA and Marcelli M: CUDC-101, a novel inhibitor of Full-length androgen receptor (flAR) and androgen receptor variant 7 (AR-V7) activity: Mechanism of action and in vivo efficacy. Horm Cancer. 7:196–210. 2016.PubMed/NCBI View Article : Google Scholar

Lai CJ, Bao R, Tao X, Wang J, Atoyan R, Qu H, Wang DG, Yin L, Samson M, Forrester J, et al: CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res. 70:3647–3656. 2010.PubMed/NCBI View Article : Google Scholar

Li X, Kamenecka TM and Cameron MD: Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. Drug Metab Dispos. 38:1238–1245. 2010.PubMed/NCBI View Article : Google Scholar

Goehringer N, Biersack B, Peng Y, Schobert R, Herling M, Ma A, Nitzsche B and Höpfner M: Anticancer activity and mechanisms of action of new chimeric EGFR/HDAC-inhibitors. Int J Mol Sci. 22(8432)2021.PubMed/NCBI View Article : Google Scholar

Hu C, Xia H, Bai S, Zhao J, Edwards H, Li X, Yang Y, Lyu J, Wang G, Zhan Y, et al: CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action. J Cell Mol Med. 24:7239–7253. 2020.PubMed/NCBI View Article : Google Scholar

Wu CP, Hsieh YJ, Hsiao SH, Su CY, Li YQ, Huang YH, Huang CW, Hsieh CH, Yu JS and Wu YS: Human ATP-binding cassette transporter ABCG2 confers resistance to CUDC-907, a dual inhibitor of histone deacetylase and phosphatidylinositol 3-Kinase. Mol Pharm. 13:784–794. 2016.PubMed/NCBI View Article : Google Scholar

Evans LW and Ferguson BS: Food bioactive HDAC inhibitors in the epigenetic regulation of heart failure. Nutrients. 10(1120)2018.PubMed/NCBI View Article : Google Scholar

Lauri C, Chiurchioni L, Russo VM, Zannini L and Signore A: PSMA expression in solid tumors beyond the prostate gland: Ready for theranostic applications? J Clin Med. 11(6590)2022.PubMed/NCBI View Article : Google Scholar

Uijen MJM, Derks YHW, Merkx RIJ, Schilham MGM, Roosen J, Prive BM, van Lith SAM, van Herpen CML, Gotthardt M, Heskamp S, et al: PSMA radioligand therapy for solid tumors other than prostate cancer: Background, opportunities, challenges, and first clinical reports. Eur J Nucl Med Mol Imaging. 48:4350–4368. 2021.PubMed/NCBI View Article : Google Scholar

Kasperzyk JL, Finn SP, Flavin R, Fiorentino M, Lis R, Hendrickson WK, Clinton SK, Sesso HD, Giovannucci EL, Stampfer MJ, et al: Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev. 22:2354–2363. 2013.PubMed/NCBI View Article : Google Scholar

Heskamp S, Hernandez R, Molkenboer-Kuenen JDM, Essler M, Bruchertseifer F, Morgenstern A, Steenbergen EJ, Cai W, Seidl C, McBride WJ, et al: α-versus β-emitting radionuclides for pretargeted radioimmunotherapy of carcinoembryonic antigen-expressing human colon cancer xenografts. J Nucl Med. 58:926–933. 2017.PubMed/NCBI View Article : Google Scholar

Sheehan B, Guo C, Neeb A, Paschalis A, Sandhu S and de Bono JS: Prostate-specific membrane antigen biology in lethal prostate cancer and its therapeutic implications. Eur Urol Focus. 8:1157–1168. 2022.PubMed/NCBI View Article : Google Scholar

Zacherl MJ, Gildehaus FJ, Mittlmeier L, Boning G, Gosewisch A, Wenter V, Unterrainer M, Schmidt-Hegemann N, Belka C, Kretschmer A, et al: First clinical results for PSMA-Targeted α-therapy using 225Ac-PSMA-I&T in Advanced-mCRPC patients. J Nucl Med. 62:669–674. 2021.PubMed/NCBI View Article : Google Scholar

Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, Davis C, Mahapane J, Corbett C, Vorster M and Morgenstern A: 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: A pilot study. Eur J Nucl Med Mol Imaging. 46:129–138. 2019.PubMed/NCBI View Article : Google Scholar

Tagawa ST, Thomas C, Sartor AO, Sun M, Stangl-Kremser J, Bissassar M, Vallabhajosula S, Huicochea Castellanos S, Nauseef JT, Sternberg CN, et al: Prostate-specific membrane antigen-targeting alpha emitter via antibody delivery for metastatic castration-resistant prostate cancer: A phase I dose-escalation study of 225Ac-J591. J Clin Oncol. 42:842–581. 2024.PubMed/NCBI View Article : Google Scholar

Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I and Wester HJ: 177Lu-Labeled Prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: Safety and efficacy. J Nucl Med. 57:1006–1013. 2016.PubMed/NCBI View Article : Google Scholar

Sandhu S, Joshua AM, Emmett L, Spain LA, Horvath L, Crumbaker M, Anton A and Hofman MS: PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 40(5017)2022.

Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, Bilen MA, Lolkema MP, Adra N, Rottey S, et al: A phase I study of acapatamab, a Half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer. Clin Cancer Res. 30:1488–1500. 2024.PubMed/NCBI View Article : Google Scholar

Hummel HD, Kufer P, Grullich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, Goebeler ME, Miller K, de Santis M, Loidl W, et al: Pasotuxizumab, a BiTE^® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. Immunotherapy. 13:125–141. 2021.PubMed/NCBI View Article : Google Scholar

De Bono JS, Fong L, Beer TM, Gao X, Geynisman DM, Burris III HA, Strauss JF, Courtney KD, Quinn DI, VanderWeele DJ, et al: Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 39(5013)2021.

Sandhu S, Joshua AM, Emmett L, Crumbaker M, Bressel M, Huynh R, Banks PD, Wallace R, Hamid A, Inderjeeth AJ, et al: LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 41(5005)2023.

Xiao X, Lao XM, Chen MM, Liu RX, Wei Y, Ouyang FZ, Chen DP, Zhao XY, Zhao Q, Li XF, et al: PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 6:546–559. 2016.PubMed/NCBI View Article : Google Scholar

Salvi S, Fontana V, Boccardo S, Merlo DF, Margallo E, Laurent S, Morabito A, Rijavec E, Dal Bello MG, Mora M, et al: Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother. 61:1463–1472. 2012.PubMed/NCBI View Article : Google Scholar

Seidel JA, Otsuka A and Kabashima K: Anti-PD-1 and Anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations. Front Oncol. 8(86)2018.PubMed/NCBI View Article : Google Scholar

Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, et al: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15:700–712. 2014.PubMed/NCBI View Article : Google Scholar

Powles T, Yuen KC, Gillessen S, Kadel EE III, Rathkopf D, Matsubara N, Drake CG, Fizazi K, Piulats JM, Wysocki PJ, et al: Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: A randomized phase 3 trial. Nat Med. 28:144–153. 2022.PubMed/NCBI View Article : Google Scholar

Sharma P, Pachynski RK, Narayan V, Flechon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, et al: Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650). J Clin Oncol. 37(142)2019.

Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, et al: Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic Chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 35:40–47. 2017.PubMed/NCBI View Article : Google Scholar

Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Ejadi S, Wallmark JM, Keam B, Delord JP, Aggarwal R, et al: Pembrolizumab for advanced prostate adenocarcinoma: Findings of the KEYNOTE-028 study. Ann Oncol. 29:1807–1813. 2018.PubMed/NCBI View Article : Google Scholar

Antonarakis ES, Piulats JM, Gross-Goupil M, Goh JC, Vaishampayan UN, De Wit R, Alanko T, Fukasawa S, Tabata K, Feyerabend S, et al: Update on KEYNOTE-199, cohorts 1-3: Pembrolizumab (pembro) for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 38(104)2020.

Hoimes CJ, Graff JN, Tagawa ST, Hwang C, Kilari D, Tije AJT, Omlin A, McDermott RS, Vaishampayan UN, Elliott T, et al: KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 38(5543)2020.

Yu EY, Piulats JM, Gravis G, Laguerre B, Arija JAA, Oudard S, Fong PCC, Kolinsky MP, Augustin M, Feyerabend S, et al: KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 38(100)2020.

Berry WR, Fong PCC, Piulats JM, Appleman LJ, Conter HJ, Feyerabend S, Shore ND, Gravis G, Laguerre B, Gurney H, et al: KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol. 38(102)2020.

Stein M, Fong L, Tutrone R, Mega A, Lam ET, Vangala S, Dennie J, Petit R, Gutierrez A, Hayes S and Haas N: KEYNOTE-046: Effects of ADXS-PSA with or without pembrolizumab on survival and antigen spreading in metastatic, castration-resistant prostate cancer patients. Cancer Res. 79(CT098)2019.

van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, et al: Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial. Lancet Oncol. 13:509–517. 2012.PubMed/NCBI View Article : Google Scholar

Ross AE, Hurley PJ, Tran PT, Rowe SP, Benzon B, Neal TO, Chapman C, Harb R, Milman Y, Trock BJ, et al: A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 23:184–193. 2020.PubMed/NCBI View Article : Google Scholar

van Wilpe S, Kloots ISH, Slootbeek PHJ, den Brok M, Westdorp H, Franken MD, Coskunturk M, Osinga T, Bloemendal H, Adema G, et al: Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: Primary analysis of the phase II INSPIRE trial. Ann Oncol. 35:1126–1137. 2024.PubMed/NCBI View Article : Google Scholar

Wang XH, Wang ZQ, Mu ZY, Zhu LP, Zhong CF and Guo S: The efficacy and safety of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. Medicine (Baltimore). 101(e29715)2022.PubMed/NCBI View Article : Google Scholar

McNeel DG, Eickhoff JC, Wargowski E, Zahm C, Staab MJ, Straus J and Liu G: Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 9:25586–25596. 2018.PubMed/NCBI View Article : Google Scholar

Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, et al: Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial. Lancet Oncol. 13:501–508. 2012.PubMed/NCBI View Article : Google Scholar

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Aafety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 28:3167–3175. 2010.PubMed/NCBI View Article : Google Scholar

Aguiar PN Jr, Santoro IL, Tadokoro H, de Lima Lopes G, Filardi BA, Oliveira P, Mountzios G and de Mello RA: The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: A network meta-analysis. Immunotherapy. 8:479–488. 2016.PubMed/NCBI View Article : Google Scholar

Karja V, Aaltomaa S, Lipponen P, Isotalo T, Talja M and Mokka R: Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res. 25:4435–4438. 2005.PubMed/NCBI

Ness N, Andersen S, Valkov A, Nordby Y, Donnem T, Al-Saad S, Busund LT, Bremnes RM and Richardsen E: Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer. Prostate. 74:1452–1461. 2014.PubMed/NCBI View Article : Google Scholar

Sorrentino C, Musiani P, Pompa P, Cipollone G and Di Carlo E: Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients. Clin Cancer Res. 17:1571–1581. 2011.PubMed/NCBI View Article : Google Scholar

Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y and Sharma P: Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell. 179:1177–1190.e13. 2019.PubMed/NCBI View Article : Google Scholar

Claps M, Mennitto A, Guadalupi V, Sepe P, Stellato M, Zattarin E, Gillessen SS, Sternberg CN, Berruti A, De Braud FGM, et al: Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. Cancer Treat Rev. 88(102057)2020.PubMed/NCBI View Article : Google Scholar

Valabrega G, Scotto G, Tuninetti V, Pani A and Scaglione F: Differences in PARP inhibitors for the treatment of ovarian cancer: Mechanisms of action, pharmacology, safety, and efficacy. Int J Mol Sci. 22(4203)2021.PubMed/NCBI View Article : Google Scholar

Chan CY, Tan KV and Cornelissen B: PARP inhibitors in cancer diagnosis and therapy. Clin Cancer Res. 27:1585–1594. 2021.PubMed/NCBI View Article : Google Scholar

Thiery-Vuillemin A, de Bono J, Hussain M, Roubaud G, Procopio G, Shore N, Fizazi K, Dos Anjos G, Gravis G, Joung JY, et al: Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): An open-label, randomised, phase 3 trial. Lancet Oncol. 23:393–405. 2022.PubMed/NCBI View Article : Google Scholar

de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, et al: Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 382:2091–2102. 2020.PubMed/NCBI View Article : Google Scholar

Thiery-Vuillemin A, Oya M, Procopio G, De Menezes JJ, Colagiovanni Girotto G, Ghatalia P, Nole F, Din O, Spiegelhalder P, Mincik I, et al: Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial. J Clin Oncol. 40(5050)2022.

Thiery-Vuillemin ASF, Saad F, Armstrong AJ, Oya M, Maia Vianna KC, Özgüroğlu M, Gedye C, Buchschacher GL, Lee JY, Emmenegger U, et al: Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial. J Clin Oncol. 40(5019)2022.

Chen X, Pan Y, Wang Q, Ren C, Li M, Hao X and Liu X: Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer. Front Endocrinol (Lausanne). 14(1225033)2023.PubMed/NCBI View Article : Google Scholar

Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, et al: Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol. 38:3763–3772. 2020.PubMed/NCBI View Article : Google Scholar

Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, Voog EG, Bryce AH, McDermott R, Ricci F, et al: Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: Analysis from the phase II TRITON2 study. Clin Cancer Res. 26:2487–2496. 2020.PubMed/NCBI View Article : Google Scholar

Rao A, Morris D, Assikis VJ, Gopalji Jha G, Ryan CJ, Ablaza JA, Habeck J, Loehr A, Xiao J, Gangolli EA, et al: Rucaparib plus enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Pharmacokinetics (PK) and safety data from the phase Ib RAMP study. J Clin Oncol. 39(79)2021.

Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, et al: Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): A multicentre, open-label, phase 2 trial. Lancet Oncol. 23:362–373. 2022.PubMed/NCBI View Article : Google Scholar

Chi KN, Rathkopf DE, Raymond Smith M, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Juliana Gomes A, Roubaud G, et al: Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. J Clin Oncol. 40(12)2022.

Agarwal N, Azad A, Shore ND, Carles J, Fay AP, Dunshee C, Karsh LI, Paccagnella ML, Santo ND, Elmeliegy M, et al: Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future Oncol. 18:425–436. 2022.PubMed/NCBI View Article : Google Scholar

Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, et al: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer. 6(141)2018.PubMed/NCBI View Article : Google Scholar

Yu E, Piulats JM, Gravis G, Fong P, Todenhöfer T, Laguerre B, Arranz J, Oudard S, Massard C, Stoeckle M, et al: 73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis. Ann Oncol. 32 (Suppl)(S387)2021.

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, et al: Integrative clinical genomics of advanced prostate cancer. Cell. 161:1215–1228. 2015.PubMed/NCBI View Article : Google Scholar

Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, et al: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 19:575–586. 2011.PubMed/NCBI View Article : Google Scholar

Sirico M, D'Angelo A, Gianni C, Casadei C, Merloni F and De Giorgi U: Current state and future challenges for PI3K inhibitors in cancer therapy. Cancers (Basel). 15(703)2023.PubMed/NCBI View Article : Google Scholar

Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, Massard C, Matsubara N, Alekseev B, Parnis F, et al: Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): A multicentre, randomised, double-blind, phase 3 trial. Lancet. 398:131–142. 2021.PubMed/NCBI View Article : Google Scholar

Sarker D, Dawson NA, Aparicio AM, Dorff TB, Pantuck AJ, Vaishampayan UN, Henson L, Vasist L, Roy-Ghanta S, Gorczyca M, et al: A Phase I, Open-label, Dose-finding study of GSK2636771, a PI3Kβ inhibitor, administered with enzalutamide in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 27:5248–5257. 2021.PubMed/NCBI View Article : Google Scholar

Pacey S, Shah N, Daviesbr BR, Bratt O, Warren A, Davies RD, Gnanapragasam VJ, Ingle S, Stearn S, Machin A, et al: A pharmacodynamic biomarker study of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (CANCAP02). J Clin Oncol. 36(5801)2018.

Graham L, Banda K, Torres A, Carver BS, Chen Y, Pisano K, Shelkey G, Curley T, Scher HI, Lotan TL, et al: A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Invest New Drugs. 36:458–467. 2018.PubMed/NCBI View Article : Google Scholar

Kemp Bohan PM, Cindass JL, Chick RC, Vreeland TJ, Hale DF, Hickerson A, Clifton GT, Peoples GE and Liss M: Results of a phase Ib trial of encapsulated rapamycin in prostate cancer patients under active surveillance to prevent progression. J Clin Oncol. 38(34)2020.PubMed/NCBI View Article : Google Scholar

Narayan V, Vapiwala N, Subramanian P, Christodouleas JP, Bekelman JE, Mick R, Walicki M, Ciconte J, Rajendran RR and Haas NB: Phase I trial of everolimus plus radiation therapy for salvage treatment of biochemical recurrence in prostate cancer patients following prostatectomy. J Clin Oncol. 34(16617)2016.PubMed/NCBI View Article : Google Scholar

Sweeney CJ, Percent IJ, Babu S, Cultrera JL, Mehlhaff BA, Goodman OB, Morris DS, Schnadig ID, Albany C, Shore ND, et al: Phase Ib/II study of enzalutamide with samotolisib (LY3023414) or placebo in patients with metastatic Castration-resistant prostate cancer. Clin Cancer Res. 28:2237–224. 2022.PubMed/NCBI View Article : Google Scholar

Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, et al: A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 13:113–123. 2015.PubMed/NCBI View Article : Google Scholar

Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN Jr and Pan CX: A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 122:1897–1904. 2016.PubMed/NCBI View Article : Google Scholar

Vaishampayan U, Shevrin D, Stein M, Heilbrun L, Land S, Stark K, Li J, Dickow B, Heath E and Smith D: Phase II trial of carboplatin, everolimus, and prednisone in metastatic castration-resistant prostate cancer pretreated with docetaxel chemotherapy: A prostate cancer clinical trial consortium study. Urology. 86:1206–1211. 2015.PubMed/NCBI View Article : Google Scholar

Rathkopf DE, Slovin SF, Morris MJ, Danila DC, Delacruz A, Shelkey G, DeNunzio M, McLaughlin B and Scher H: Targeting reciprocal feedback inhibition: Apalutamide and everolimus in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 15(204)2017.

Coleman N, Moyers JT, Harbery A, Vivanco I and Yap TA: Clinical development of AKT inhibitors and associated predictive biomarkers to guide patient treatment in cancer medicine. Pharmgenomics Pers Med. 14:1517–1535. 2021.PubMed/NCBI View Article : Google Scholar

Lockney NA, Henderson RH, Swarts SG, Zhang Z, Zhang B, Li J, Zlotecki RA, Morris CG, Casey-Sawicki KA and Okunieff PG: Measuring radiation toxicity using circulating Cell-free DNA in prostate cancer patients. Int J Part Ther. 8:28–35. 2022.PubMed/NCBI View Article : Google Scholar